A tendon-cell experiment can explain a possible biological mechanism without showing that a torn human tendon heals faster. Readers evaluating BPC-157 should keep those two questions separate: what happens in a laboratory system, and what happens to a person with a particular injury?
The mechanism study
In a primary tendon fibroblast experiment, researchers observed increased growth-hormone-receptor expression in cultured rat tendon cells and examined responses to added growth hormone. These findings concern cell signaling under experimental conditions. They do not measure human return to work, reinjury or the mechanical strength of a repaired tendon.
A receptor result is not a clinical endpoint. More of a receptor does not automatically tell us whether the complete tissue becomes stronger, how fibers organize, or whether an injured person can safely tolerate a greater workload.
The steps between a cell and a patient
Several links would need to hold for the proposed mechanism to become a useful treatment. The relevant molecule would have to reach the affected tissue. The tissue response would have to be beneficial in the specific stage and type of injury. That response would then have to produce better outcomes than appropriate comparison care without unacceptable harms.
Those are questions for additional experiments, not conclusions hidden inside the cell study. A laboratory effect can be real while its practical importance remains uncertain.
Why postoperative claims need their own evidence
Surgical repair introduces factors not represented by isolated cells: the procedure itself, protection of the repair, rehabilitation and the timing of loading. An experiment on cultured fibroblasts cannot determine whether any of those clinical decisions should change.
A persuasive human study would distinguish acute tears from longstanding tendon symptoms, describe accompanying care, and measure both function and complications. It should make clear whether any apparent improvement persists after the study intervention ends.
The useful reading of this research is therefore specific: it offers a mechanistic lead. It does not establish a personal regimen, justify combining BPC-157 with growth-hormone-active compounds, or replace the treating team's assessment of healing.